All In Biotech

Drug Trial Radar · NCT06737536

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

A Single- and Multiple-ascending Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of NNC0662-0419 in Participants Living With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Dec 18, 2024

Primary completion

Jul 26, 2025

Study completion Jul 26, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.

Conditions

  • Overweight
  • Obesity

Interventions

  • NNC0662-0419Drug

    Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.

  • Placebo (NNC0662-0419)Other

    Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of treatment emergent adverse events (TEAE)Time frame: From timing of dosing on day 1 until completion of the end of study visit (up to 6 weeks)
  2. Part B: Number of treatment-emergent adverse events (TEAE)Time frame: From timing of dosing on day 1 until completion of the end of study visit (up to 9 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Lincoln

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.